Inside Exact Science’s Next Big Bet - One Blood Draw, More than 50 Cancers

This podcast features Jonathan Palmer from Bloomberg Intelligence interviewing Kevin Conroy, CEO of Exact Sciences, a leader in cancer diagnostics. They discuss the evolution of Exact Sciences from its early days to its current status, highlighting key milestones such as the development and launch of Cologuard. The conversation covers Exact Science's new multi-cancer early detection test, Cancerguard, including its functionality, specificity, pricing, and the company's strategy for commercialization and reimbursement. They also delve into Cologuard Plus, its improvements over the original Cologuard, and the growth drivers for the Cologuard franchise. The discussion shifts to precision oncology, focusing on OncoDetect and the market for minimal residual disease (MRD) testing, as well as the company's approach to colorectal cancer blood tests and its partnership with Freenome. Finally, they touch on Exact Sciences' future direction, its vision for eradicating cancer, and Conroy's evolving role as a leader within the company.